The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia
Official Title: Treatment of Relapsed Acute Myelogenous Leukemia Consisting of Intermediate Dose Cytosine Arabinoside (ARA-C) Plus Interspaced Continuous Infusion Idarubicin, Followed by Continuous Infusion of Low-Dose ARA-C, A Phase II Study by the EORTC-LCG
Study ID: NCT00003758
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy consisting of cytarabine plus idarubicin in treating patients who have relapsed acute myelogenous leukemia.
Detailed Description: OBJECTIVES: I. Assess the feasibility and efficacy of intermediate dose cytarabine plus idarubicin followed by low dose cytarabine in patients with relapsed acute myelogenous leukemia. OUTLINE: This is a multicenter study. Patients receive intermediate dose cytarabine IV over 2 hours twice a day on days 1-5, idarubicin IV over 24 hours on days 1, 3, and 5, and low dose cytarabine IV over 24 hours on days 6-15. If patients achieve complete remission by day 35, this regimen is repeated once. If patients achieve partial remission by day 35, this regimen is repeated, except with an additional day of idarubicin on day 7. If these patients then achieve complete remission by day 70, the regimen is repeated. Patients may then undergo stem cell transplantation within 6 months of achieving complete remission. Patients who have an HLA identical sibling available receive an allogeneic transplant; others receive an autologous transplant. Patients are followed monthly for 1 year, every 3 months for 3 years, then every 6 months thereafter. PROJECTED ACCRUAL: A total of 24-60 patients will be accrued for this study.
Minimum Age: 15 Years
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Algemeen Ziekenhuis Middelheim, Antwerp, , Belgium
A.Z. St. Jan, Brugge, , Belgium
Institut Jules Bordet, Brussels, , Belgium
Universitair Ziekenhuis Antwerpen, Edegem, , Belgium
Medical School/University of Zagreb, Zagreb, , Croatia
University Hospital Rebro, Zagreb, , Croatia
Hotel Dieu de Paris, Paris, , France
Hopital Necker, Paris, , France
Ospedale San Eugenio, Rome, , Italy
Policlinico A. Gemelli - Universita Cattolica del Sacro Cuore, Rome, , Italy
Groot Ziekengasthuis 's-Hertogenbosch, 's-Hertogenbosch, , Netherlands
Leiden University Medical Center, Leiden, , Netherlands
University Medical Center Nijmegen, Nijmegen, , Netherlands
Sint Joseph Ziekenhuis, Veldhoven, , Netherlands
Hospital Escolar San Joao, Porto, , Portugal
Ibn-i Sina Hospital, Ankara Univeristy, Ankara, , Turkey
Name: Petra Muus, MD, PhD
Affiliation: Universitair Medisch Centrum St. Radboud - Nijmegen
Role: STUDY_CHAIR